VNDA Latest Headlines

Regulatory Hurdles Cloud Vanda Pharmaceuticals’ Prospects for Bysanti and Imsidolimab FDA Approvals

at www.tipranks.com (Fri, 13-Feb 1:02 AM)

Vanda Pharmaceuticals Eyes Growth on Robust Fanapt® Sales and Regulatory Milestones as 2026 Approaches

Market Chameleon (Thu, 12-Feb 8:24 AM)

Vanda Pharmaceuticals Balances Growth With Rising Risks

at www.tipranks.com (Thu, 12-Feb 7:15 PM)

Vanda declines on Q4 results, weak 2026 revenue guidance

at seekingalpha.com (Thu, 12-Feb 11:00 AM)

Vanda Pharmaceuticals GAAP EPS of -$2.39 misses by $1.07, revenue of $57.22M misses by $2.05M

at seekingalpha.com (Wed, 11-Feb 4:03 PM)

Here are the major earnings after the close Wednesday

at seekingalpha.com (Wed, 11-Feb 10:00 AM)

FDA Approves Vanda’s NEREUS—First Novel Motion Sickness Drug in 40 Years Spurs Historic Milestone

Market Chameleon (Wed, 31-Dec 9:53 AM)

FDA Application Submission for Imsidolimab Marks a Milestone for Vanda—Phase 3 Data Suggest Durable Benefits for GPP Patients

Market Chameleon (Mon, 15-Dec 11:44 AM)

Vanda's Imsidolimab Application Targets FDA Priority Review: New Hope for Generalized Pustular Psoriasis

Market Chameleon (Mon, 15-Dec 8:37 AM)

FDA Clears Path for Vanda’s Tradipitant: Clinical Hold Lifted and PDUFA Decision Looms

Market Chameleon (Fri, 5-Dec 11:10 AM)

FDA Clears Path for Vanda's Tradipitant in Motion Sickness: PDUFA Date Approaches, Marking First Major Advancement in 40 Years

Market Chameleon (Fri, 5-Dec 8:39 AM)

Tradipitant Study Shows 50% Drop in GLP-1 Induced Vomiting—VNDA Positioned for $50B+ Market Opportunity

Market Chameleon (Tue, 18-Nov 10:31 AM)